Singapore collaboration advances population-scale proteomics research

Thermo Fisher Scientific has entered a strategic collaboration with Precision Health Research, Singapore (PRECISE) to support the PRECISE-SG100K study, a major population-scale research programme designed to generate deeper insight into disease biology across Singapore’s diverse population.

As large-scale biobanks become increasingly important to national healthcare strategies, researchers are turning to proteomics and advanced analytical approaches to better understand how diseases emerge and progress. The PRECISE-SG100K study has recruited more than 100,000 participants and aims to create a long-term resource linking biological, environmental and health data.

Under the collaboration, Thermo Fisher will contribute an integrated proteomics approach combining targeted protein analysis with large-scale discovery methods. By bringing complementary technologies together within a single framework, researchers aim to improve reproducibility, strengthen evidence generation and uncover biological signals that may otherwise remain hidden.

The project reflects a broader shift in precision medicine research, where large population datasets are increasingly being used to identify patterns associated with disease risk and progression. Applied at scale, these approaches could help improve patient stratification, support earlier disease detection and accelerate the translation of research findings into healthcare applications.

John Chambers, PhD, Chief Scientific Officer at PRECISE and lead principal investigator of the PRECISE-SG100K study, said: “By applying this integrated proteomics approach across our national cohort, we gain a dynamic view of disease biology within Singapore’s uniquely diverse population.” He added that the approach could strengthen efforts to identify early molecular signals linked to disease and improve understanding of risk across different populations.

The initiative also builds on Thermo Fisher’s wider involvement in large biobank programmes worldwide, including population-scale projects in the UK, Finland and the United States. Collectively, these studies represent analyses involving more than one million samples and continue to shape how researchers investigate disease across diverse populations.

More information online